Glycosides, Natural or Synthetic, and Derivatives (Other)

The regulatory pathway depends on the specific compound and its intended use. Cardiac glycosides (e.g., digoxin) and other pharmaceutical-active glycosides require FDA drug admissibility review and must originate from registered facilities. Steviol glycosides and similar food-grade compounds are reviewed under FDA food additive or GRAS frameworks. Importers should document the intended use on the entry and ensure the Certificate of Analysis specifies the grade and application. Consult a licensed customs broker or regulatory counsel for admissibility guidance.

Concentrated plant extracts that contain glycosides as their active constituents may classify in Chapter 13 (vegetable saps and extracts) rather than Chapter 29 if they are not chemically isolated or purified. Chapter 29 requires that the compound be a chemically defined substance — meaning a single molecular entity at a defined purity level. Standardized botanical extracts with a specified glycoside content but containing other plant-matrix components typically fall outside Chapter 29. A binding ruling from CBP is advisable for borderline extract products.